Teva and MedinCell Announce FDA Approval of UZEDY (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in Adults

This new treatment provides adults living with schizophrenia a long-acting formulation that offers flexible 1- and 2-month dosing intervals1 In a Phase 3 clinical trial, UZEDY demonstrated

Related Keywords

United States ,France ,Russia ,Ukraine ,Asmal ,Chechnya And Ingushetiya ,American ,Richard Francis ,Nicolas Merigeau Newcap ,Christophe Douat ,Medincell Euronext ,David Heuz ,Eden Klein ,Yael Ashman ,Christoph Correll ,Sanjeev Sharma ,Kelley Dougherty ,National Pregnancy Registry For Atypical Antipsychotics ,Global Health ,Drug Administration ,Us Department Of Justice ,Teva Pharmaceutical Industries Ltd ,Teva Pharmaceuticals ,Teva Neuroscience Inc ,Us National Institutes Of Health ,Zucker School Of Medicine ,Teva Pharmaceutical Industries ,Risperidone Subcutaneous Extended Release Study ,Maintenance Treatment ,Zucker School ,Wholesale Acquisition Cost ,Trial Results ,Adverse Reactions ,Malignant Syndrome ,Motor Impairment ,National Pregnancy Registry ,Atypical Antipsychotics ,Hepatic Impairment ,Prescribing Information ,Pharmaceutical Industries ,Private Securities Litigation Reform Act ,Sherman Act ,Annual Report ,Looking Statements ,Current Prescribing ,Placebo Controlled Study ,Subcutaneous Use ,Adolescent Patients With Schizophrenia ,Teva Neuroscience ,Healthcare Professional Preferences ,Long Acting Injectable Antipsychotic Agents ,Victor Delouvrier ,Newcap Media Relations ,Teva ,Medincell ,Nnounce ,Approval ,Zedy ,Risperidone ,Xtended ,Release ,Injectable ,Suspension ,Song ,Acting ,Subcutaneous ,Atypical ,Antipsychotic ,Injection ,Treatment ,Schizophrenia ,Adults ,